Insmed (NASDAQ:INSM) Price Target Raised to $135.00

Key Points

• JPMorgan Chase & Co. has increased its price target for Insmed from $111.00 to $135.00, maintaining an "overweight" rating and suggesting a potential upside of 4.80% from the previous close.
• The company reported a quarterly loss of ($1.70) earnings per share (EPS), missing the consensus estimate while achieving revenues of $107.42 million, exceeding expectations.
• Insider trading activity saw CEO William Lewis and CFO Sara Bonstein selling significant shares recently, with total insider sales amounting to approximately $47.78 million over the last ninety days.

Insmed (NASDAQ:INSM - Get Free Report) had its price target increased by equities research analysts at JPMorgan Chase & Co. from $111.00 to $135.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 4.80% from the company's previous close.

Other analysts have also issued reports about the stock. Morgan Stanley restated an "equal weight" rating and set a $126.00 price objective on shares of Insmed in a research note on Wednesday, August 13th. UBS Group lifted their price target on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Leerink Partners lifted their price target on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. William Blair initiated coverage on shares of Insmed in a research note on Wednesday. They issued an "outperform" rating for the company. Finally, HC Wainwright lifted their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $131.29.

Insmed Stock Up 1.3%

Shares of Insmed stock traded up $1.6060 during trading on Wednesday, hitting $128.8160. The company's stock had a trading volume of 693,259 shares, compared to its average volume of 2,818,732. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a fifty day simple moving average of $105.47 and a two-hundred day simple moving average of $84.62. The company has a market capitalization of $27.23 billion, a PE ratio of -22.57 and a beta of 0.95. Insmed has a 52 week low of $60.40 and a 52 week high of $130.13.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm's revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities research analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 129,805 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. The trade was a 35.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. This trade represents a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 497,829 shares of company stock worth $47,778,638 over the last ninety days. 3.00% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

A number of large investors have recently made changes to their positions in the stock. Hilltop National Bank purchased a new stake in Insmed in the second quarter worth about $28,000. ORG Partners LLC increased its holdings in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 196 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Insmed in the 2nd quarter worth approximately $33,000. Cullen Frost Bankers Inc. increased its holdings in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the period. Finally, Elequin Capital LP acquired a new position in Insmed in the 4th quarter worth approximately $28,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.